CIBC Private Wealth Group LLC Boosts Position in Becton, Dickinson and Company $BDX

CIBC Private Wealth Group LLC raised its position in Becton, Dickinson and Company (NYSE:BDX) by 2.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 111,993 shares of the medical instruments supplier’s stock after purchasing an additional 3,201 shares during the quarter. CIBC Private Wealth Group LLC’s holdings in Becton, Dickinson and Company were worth $20,962,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the business. CIBC Bancorp USA Inc. acquired a new position in Becton, Dickinson and Company in the third quarter valued at about $7,401,000. Centaurus Financial Inc. grew its stake in shares of Becton, Dickinson and Company by 115.9% in the third quarter. Centaurus Financial Inc. now owns 3,767 shares of the medical instruments supplier’s stock worth $705,000 after acquiring an additional 2,022 shares in the last quarter. First Affirmative Financial Network grew its stake in Becton, Dickinson and Company by 5.3% during the 3rd quarter. First Affirmative Financial Network now owns 1,240 shares of the medical instruments supplier’s stock worth $232,000 after purchasing an additional 62 shares in the last quarter. Caerus Investment Advisors LLC purchased a new stake in shares of Becton, Dickinson and Company during the third quarter worth approximately $367,000. Finally, Faithward Advisors LLC purchased a new stake in shares of Becton, Dickinson and Company in the 3rd quarter valued at approximately $235,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Price Performance

Shares of NYSE:BDX opened at $156.56 on Friday. Becton, Dickinson and Company has a 52 week low of $127.59 and a 52 week high of $187.35. The business has a fifty day simple moving average of $186.50 and a 200-day simple moving average of $189.08. The company has a quick ratio of 0.58, a current ratio of 1.05 and a debt-to-equity ratio of 0.67. The company has a market cap of $44.58 billion, a P/E ratio of 25.54, a P/E/G ratio of 11.46 and a beta of 0.24.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share for the quarter, topping the consensus estimate of $2.81 by $0.10. The business had revenue of $5.25 billion for the quarter, compared to analyst estimates of $5.15 billion. Becton, Dickinson and Company had a net margin of 8.01% and a return on equity of 15.76%. The company’s revenue was up 1.6% on a year-over-year basis. During the same period in the prior year, the firm posted $3.43 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. Equities research analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company announced that its board has initiated a stock repurchase program on Tuesday, January 27th that allows the company to buyback $10.00 million in shares. This buyback authorization allows the medical instruments supplier to purchase up to 0% of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s leadership believes its shares are undervalued.

Becton, Dickinson and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 31st. Shareholders of record on Tuesday, March 10th will be given a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date of this dividend is Tuesday, March 10th. Becton, Dickinson and Company’s payout ratio is 68.52%.

Insider Transactions at Becton, Dickinson and Company

In other news, EVP Michael David Garrison sold 1,610 shares of the firm’s stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $207.46, for a total value of $334,010.60. Following the transaction, the executive vice president directly owned 12,095 shares in the company, valued at $2,509,228.70. This trade represents a 11.75% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Bertram L. Scott sold 953 shares of Becton, Dickinson and Company stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $182.61, for a total value of $174,027.33. Following the completion of the transaction, the director directly owned 36,763 shares in the company, valued at $6,713,291.43. This represents a 2.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 2,787 shares of company stock valued at $551,391. 0.40% of the stock is owned by company insiders.

Analyst Ratings Changes

Several brokerages have recently weighed in on BDX. Jefferies Financial Group cut their target price on Becton, Dickinson and Company from $220.00 to $190.00 and set a “buy” rating on the stock in a research report on Tuesday, February 10th. Morgan Stanley raised their price objective on shares of Becton, Dickinson and Company from $197.00 to $210.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 2nd. Stifel Nicolaus lifted their target price on Becton, Dickinson and Company from $210.00 to $215.00 and gave the company a “buy” rating in a research note on Wednesday, January 7th. Royal Bank Of Canada set a $172.00 price objective on shares of Becton, Dickinson and Company in a research report on Tuesday, February 10th. Finally, JPMorgan Chase & Co. reduced their price objective on shares of Becton, Dickinson and Company from $190.00 to $175.00 and set a “neutral” rating for the company in a research report on Tuesday, February 10th. Five investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $195.46.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.